J. Joseph Melenhorst

30.0k total citations · 8 hit papers
122 papers, 12.7k citations indexed

About

J. Joseph Melenhorst is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, J. Joseph Melenhorst has authored 122 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 40 papers in Immunology and 35 papers in Molecular Biology. Recurrent topics in J. Joseph Melenhorst's work include CAR-T cell therapy research (103 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Immune Cell Function and Interaction (22 papers). J. Joseph Melenhorst is often cited by papers focused on CAR-T cell therapy research (103 papers), Chronic Lymphocytic Leukemia Research (24 papers) and Immune Cell Function and Interaction (22 papers). J. Joseph Melenhorst collaborates with scholars based in United States, China and Netherlands. J. Joseph Melenhorst's co-authors include Carl H. June, Simon F. Lacey, Bruce L. Levine, Stephan A. Grupp, David L. Porter, Noelle V. Frey, Pamela A. Shaw, Zhaohui Zheng, Shannon L. Maude and Vanessa Gonzalez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

J. Joseph Melenhorst

119 papers receiving 12.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

2014 3.9k citations Shannon L. Maude, Noelle V. Frey et al. profile →
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

2015 1.3k citations David Porter, Noelle V. Frey et al. Science Translational Medicine profile →
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

2017 1.3k citations Stephen J. Schuster, Jakub Svoboda et al. profile →
Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

2018 478 citations J. Joseph Melenhorst, Simon F. Lacey et al. profile →
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

2015 434 citations Alfred L. Garfall, Simon F. Lacey et al. profile →
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation

2018 430 citations Avery D. Posey, Prachi Patel et al. profile →
Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

2018 379 citations Simon F. Lacey, Anne Marie Nelson et al. profile →
Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

2016 344 citations Shannon L. Maude, David M. Barrett et al. profile →

Peers

Countries citing papers authored by J. Joseph Melenhorst

Since Specialization

Citations

This map shows the geographic impact of J. Joseph Melenhorst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Joseph Melenhorst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Joseph Melenhorst more than expected).

Fields of papers citing papers by J. Joseph Melenhorst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Joseph Melenhorst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Joseph Melenhorst. The network helps show where J. Joseph Melenhorst may publish in the future.

Co-authorship network of co-authors of J. Joseph Melenhorst

This figure shows the co-authorship network connecting the top 25 collaborators of J. Joseph Melenhorst. A scholar is included among the top collaborators of J. Joseph Melenhorst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Joseph Melenhorst. J. Joseph Melenhorst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Fine tuning towards the next generation of engineered T cells 2025 ·Nature Biomedical Engineering ·(unknown), Patrick Ho, (unknown), Céline Grégoire, (unknown), (unknown), AnneMarie W. Block, Michael Hudecek, J. Joseph Melenhorst, Jo Caers, Maik Luu	0
2	Navigating CAR-T cell therapy long-term complications 2024 ·Nature Cancer ·Céline Grégoire, J. Joseph Melenhorst	3
3	Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models 2024 ·Cancer Immunology Research ·Paolo F. Caimi, J. Joseph Melenhorst	1
4	Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics 2024 ·Journal for ImmunoTherapy of Cancer ·Yee Peng Phoon, Jared E. Lopes, Lukas W. Pfannenstiel, C. Marcela Díaz‐Montero, (unknown), Marc S. Ernstoff, Pauline Funchain, Jennifer S. Ko, Raymond J. Winquist, Heather C. Losey, J. Joseph Melenhorst, Brian Gastman	2
5	Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice 2024 ·British Journal of Haematology ·Céline Grégoire, (unknown), Paolo F. Caimi, Jo Caers, J. Joseph Melenhorst	5
6	Challenges and opportunities of CAR T-cell therapies for CLL 2023 ·Seminars in Hematology ·Ziran Zhao, Céline Grégoire, (unknown), (unknown), J. Joseph Melenhorst	5
7	B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function? 2022 ·Science Translational Medicine ·Gregory M. Chen, J. Joseph Melenhorst, Kai Tan	13
8	Enhanced Costimulatory Signaling Improves CAR T-cell Effector Responses in CLL 2022 ·Cancer Research Communications ·McKensie Collins, In-Young Jung, Ziran Zhao, (unknown), Weimin Kong, Stefan Lundh, Joseph A. Fraietta, Arnon P. Kater, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst	11
9	Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL 2022 ·Science Advances ·Zhiliang Bai, Steven Woodhouse, Ziran Zhao, Rahul Singh Arya, Kiya W. Govek, Dongjoo Kim, Stefan Lundh, Alev Baysoy, Hongxing Sun, Yanxiang Deng, Yang Xiao, David M. Barrett, Regina M. Myers, Stephan A. Grupp, Carl H. June, Rong Fan, Pablo G. Cámara, J. Joseph Melenhorst	92
10	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma 2021 ·Clinical Cancer Research ·(unknown), Adam D. Cohen, Simon F. Lacey, Megan M. Davis, Alfred L. Garfall, J. Joseph Melenhorst, Russell Maxwell, W. Tristram Arscott, Amit Maity, Joshua Jones, John P. Plastaras, Edward A. Stadtmauer, Bruce L. Levine, Carl H. June, Michael C. Milone, Ima Paydar	23
11	Engineering-enhanced CAR T cells for improved cancer therapy 2021 ·Nature Cancer ·Michael C. Milone, Jie Xu, Sai‐Juan Chen, McKensie Collins, Jianfeng Zhou, Daniel J. Powell, J. Joseph Melenhorst	95
12	Next-generation CAR T cells to overcome current drawbacks 2020 ·International Journal of Hematology ·Stefan Lundh, Sayantan Maji, J. Joseph Melenhorst	10
13	A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells 2019 ·Blood ·Marco Ruella, David M. Barrett, Olga Shestova, Jessica Perazzelli, Avery D. Posey, Seok Jae Hong, Miroslaw Kozlowski, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill	24
14	Mechanisms of resistance to CAR T cell therapies 2019 ·Seminars in Cancer Biology ·Nathan Singh, Elena J. Orlando, Jun Xu, Jie Xu, Zev A. Binder, McKensie Collins, Donald M. O’Rourke, J. Joseph Melenhorst	28
15	Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells 2018 ·Cancer Immunology Research ·Saba Ghassemi, Selene Nuñez-Cruz, Roddy S. O’Connor, Joseph A. Fraietta, Prachi Patel, John Scholler, David M. Barrett, Stefan Lundh, Megan M. Davis, Felipe Bedoya, Changfeng Zhang, John Leferovich, Simon F. Lacey, Bruce L. Levine, Stephan A. Grupp, Carl H. June, J. Joseph Melenhorst, Michael C. Milone	212
16	Treating Relapsed / Refractory (RR) AML with Biodegradable Anti-CD123 CAR Modified T Cells 2017 ·Blood ·Katherine D. Cummins, Noelle V. Frey, Anne Marie Nelson, (unknown), Selina M. Luger, Randi Isaacs, Simon F. Lacey, Elizabeth O. Hexner, J. Joseph Melenhorst, Carl H. June, David L. Porter, Saar Gill	92
17	Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy 2017 ·Blood ·Elise A. Chong, J. Joseph Melenhorst, Jakub Svoboda, Sunita D. Nasta, Daniel J. Landsburg, Anthony R. Mato, Lifeng Tian, (unknown), Simon F. Lacey, Carl H. June, Stephen J. Schuster	17
18	Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy 2016 ·Journal of Immunological Methods ·Fangfang Chen, David T. Teachey, Edward Pequignot, Noelle V. Frey, David Porter, Shannon L. Maude, Stephan A. Grupp, Carl H. June, J. Joseph Melenhorst, Simon F. Lacey	141
19	Kinase Inhibitor Ibrutinib Prevents Cytokine-Release Syndrome after Anti-CD19 Chimeric Antigen Receptor T Cells (CART) for B Cell Neoplasms 2016 ·Blood ·Marco Ruella, Saad S. Kenderian, Olga Shestova, Michael Klichinsky, J. Joseph Melenhorst, Mariusz A. Wasik, Simon F. Lacey, Carl H. June, Saar Gill	8
20	Ruxolitinib Prevents Cytokine Release Syndrome after CART Cell Therapy without Impairing the Anti-Tumor Effect in a Xenograft Model 2016 ·Blood ·Saad S. Kenderian, Marco Ruella, Olga Shestova, Miriam Kim, Michael Klichinsky, Fang Chen, (unknown), Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Saar Gill	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact